NasdaqGM:ANIPPharmaceuticals
US Generic Drug Stocks With Domestic Manufacturing in Focus
Tariffs on imported generic drugs of up to 200% from 2029 could reshape where and how the medicines in US pharmacies are made, and that has real implications for US-based generic drug stocks. With 90% of US prescriptions filled by generics and about 70% of those sourced from overseas, investors are right to pay attention as policy pressure builds for more domestic manufacturing. This article looks at how that policy shock could affect US-based generic manufacturers and highlights three stocks...